Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

BACKGROUND: Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., de Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y. V., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., Groot Koerkamp, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989075/
https://www.ncbi.nlm.nih.gov/pubmed/33757440
http://dx.doi.org/10.1186/s12885-021-08031-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989075/
https://www.ncbi.nlm.nih.gov/pubmed/33757440
http://dx.doi.org/10.1186/s12885-021-08031-z

Ejemplares similares